School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina.
Department of Dermatology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina.
J Am Acad Dermatol. 2019 Sep;81(3):702-708. doi: 10.1016/j.jaad.2019.05.022. Epub 2019 May 13.
Few data exist to guide infliximab dosing in hidradenitis suppurativa (HS).
To determine optimal infliximab dosing for patients with HS based on treatment response and achievement of stable dosing.
Retrospective cohort study of 52 patients with HS treated with infliximab. Primary outcome was achievement of stable dosing regimen for at least 8 weeks. Secondary outcomes were time to discontinuation, time to titration, changes to inflammatory markers, and clinical response.
Thirty-five patients (67%) achieved stable dosing, most at a schedule of 10 mg/kg every 6 or 8 weeks. At 1 year from initiation, most patients (64%) required dose escalation. Patients tolerated infliximab well and achieved significant improvements in abscess and nodule count, draining sinuses, and erythrocyte sedimentation rate.
Retrospective nature and lack of HS clinical response data for many patients.
Infliximab 10 mg/kg every 6 or 8 weeks may be a reasonable starting dosage for most patients.
目前针对中重度痤疮患者，指导英夫利昔单抗剂量的相关数据较为缺乏。
基于治疗反应和稳定剂量的实现，确定中重度痤疮患者使用英夫利昔单抗的最佳剂量。
回顾性队列研究了 52 例接受英夫利昔单抗治疗的中重度痤疮患者。主要结局是至少 8 周达到稳定的治疗方案。次要结局包括停药时间、滴定时间、炎症标志物的变化和临床反应。
35 例患者（67%）达到了稳定的剂量，大多数患者的方案为每 6 或 8 周 10mg/kg。在开始治疗后的 1 年，大多数患者（64%）需要进行剂量升级。患者对英夫利昔单抗耐受良好，脓肿和结节计数、窦道引流和红细胞沉降率均有显著改善。
回顾性研究，且许多患者缺乏中重度痤疮的临床反应数据。
英夫利昔单抗每 6 或 8 周 10mg/kg 可能是大多数患者的合理起始剂量。
